Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.
Chiugo Okoye
Advertisement
Articles by Chiugo Okoye
Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
5